Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Sees Significant Decrease in Short Interest

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) saw a large decline in short interest in August. As of August 31st, there was short interest totalling 61,600 shares, a decline of 96.1% from the August 15th total of 1,570,000 shares. Based on an average trading volume of 256,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.5% of the company’s stock are short sold.

Institutional Trading of Aeglea BioTherapeutics

A number of large investors have recently bought and sold shares of AGLE. ExodusPoint Capital Management LP bought a new stake in shares of Aeglea BioTherapeutics during the fourth quarter worth $47,000. Carlyle Group Inc. bought a new position in Aeglea BioTherapeutics in the first quarter valued at about $69,000. Two Sigma Investments LP boosted its holdings in Aeglea BioTherapeutics by 280.0% in the fourth quarter. Two Sigma Investments LP now owns 393,638 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 290,049 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Aeglea BioTherapeutics by 117.0% in the second quarter. Renaissance Technologies LLC now owns 393,000 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 211,900 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its holdings in Aeglea BioTherapeutics by 46.6% in the first quarter. Sphera Funds Management LTD. now owns 646,478 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 205,641 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AGLE. Stifel Nicolaus began coverage on Aeglea BioTherapeutics in a research note on Tuesday, July 25th. They set a “buy” rating and a $22.50 target price on the stock. StockNews.com cut Aeglea BioTherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Wells Fargo & Company boosted their price target on Aeglea BioTherapeutics from $8.75 to $12.50 and gave the company an “equal weight” rating in a research note on Wednesday, August 16th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.38.

Aeglea BioTherapeutics Trading Up 6.0 %

Shares of NASDAQ AGLE opened at $14.68 on Thursday. The business has a fifty day simple moving average of $13.61 and a 200 day simple moving average of $8.67. The firm has a market capitalization of $59.42 million, a price-to-earnings ratio of -0.21 and a beta of 2.53. Aeglea BioTherapeutics has a one year low of $2.66 and a one year high of $39.00.

Aeglea BioTherapeutics (NASDAQ:AGLE) last issued its earnings results on Friday, August 11th. The biotechnology company reported ($41.50) EPS for the quarter, missing analysts’ consensus estimates of ($4.50) by ($37.00). The firm had revenue of $0.69 million during the quarter. Aeglea BioTherapeutics had a negative net margin of 22,195.36% and a negative return on equity of 132.05%. On average, research analysts anticipate that Aeglea BioTherapeutics will post 0.17 earnings per share for the current fiscal year.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.